Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Shetty, Praveenkumar K ^a   Thamake, Sanjay I ^b   Biswas, Swati ^d   Johansson, Sonny L ^c   Vishwanatha, Jamboor K ^a,b  

^a SDM COLLEGE OF MEDICAL SCIENCES AND HOSPITAL   (India)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOCORTIN 2; MESSENGER RNA; SMALL INTERFERING RNA; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL EXPANSION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEIN TRANSPORT; RECIPROCAL REGULATION; REGULATORY MECHANISM; RNA ANALYSIS; UPREGULATION;

ANNEXIN A2; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COLLAGEN; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LAMININ; LIGANDS; PHENOTYPE; PROTEOGLYCANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84866046117     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044299     Document Type: Article

References (58)

1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1): 4429-4434.
2. Tan AR, Swain SM, (2008) Therapeutic strategies for triple-negative breast cancer. Cancer J 14(6): 343-351.
3. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, et al. (2007) The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8): 2329-2334.
4. Moasser MM, (2007) The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45): 6469-6487.
5. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, et al. (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108(1): 71-77.
6. Kauraniemi P, Hautaniemi S, Autio R, Astola J, Monni O, et al. (2004) Effects of herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 23(4): 1010-1013.
7. Snoj N, Bedard PL, de Azambuja E, Cardoso F, Piccart M, (2009) Are we HER-ting for innovation in neoadjuvant breast cancer trial design? Breast Cancer Res 11(1): 201.
8. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, et al. (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to akt signaling. PLoS ONE 3(8): e3065.
9. Zhang S, Huang WC, Li P, Guo H, Poh SB, et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17(4): 461-469.
10. Zhang Y, Zhang J, (2010) Mechanisms of resistance to trastuzumab:An updated review. Chinese-German J Clin Oncol 9(11): P660.
11. Doane AS, Danso M, Lal P, Donaton M, Zhang L, et al. (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28): 3994-4008.
12. Pignon JC, Koopmansch B, Nolens G, Delacroix L, Waltregny D, et al. (2009) Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res 69(7): 2941-2949.
13. Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, et al. (2008) Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in japanese triple-negative breast cancers. BMC Cancer 8: 309.
14. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, et al. (2008) Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: Prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat.
15. Corkery B, Crown J, Clynes M, O'Donovan N, (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20(5): 862-867.
16. Finn RS, (2008) Targeting src in breast cancer. Ann Oncol 19(8): 1379-1386.
17. Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, et al. (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 122(3): 685-697.
18. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC, (2006) Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81(2): 146-156.
19. Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R, (2004) Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 53(7): 993-1000.
20. Yao H, Zhang Z, Xiao Z, Chen Y, Li C, et al. (2009) Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer 65(1): 41-48.
21. Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, et al. (2009) Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer 101(2): 287-294.
22. Duncan R, Carpenter B, Main LC, Telfer C, Murray GI, (2008) Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98(2): 426-433.
23. Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, et al. (2001) Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 21(2B): 1339-1345.
24. Banerjee AG, Liu J, Yuan Y, Gopalakrishnan VK, Johansson SL, et al. (2003) Expression of biomarkers modulating prostate cancer angiogenesis: Differential expression of annexin II in prostate carcinomas from india and USA. Mol Cancer 2: 34.
25. Valapala M, Vishwanatha JK, (2011) Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem 286 (35):: 30911-30925 doi:10.1074/jbc.M111.271155.
26. de Graauw M, Tijdens I, Smeets MB, Hensbergen PJ, Deelder AM, et al. (2008) Anexin A2 phosphorylation mediates cell scattering and branching morphogenesis via cofilin activation. Mol Cell Biol 28(3): 1029-1040.
27. Hajjar KA, Krishnan S, (1999) Annexin II: A mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med 9(5): 128-138.
28. Valapala M, Thamake SI, Vishwanatha JK, (2011) A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. J Cell Sci 124(Pt 9): 1453-1464.
29. Zhao WQ, Chen GH, Chen H, Pascale A, Ravindranath L, et al. (2003) Secretion of annexin II via activation of insulin receptor and insulin-like growth factor receptor. J Biol Chem 278(6): 4205-4215.
30. Yoo JC, Hayman MJ, (2007) Annexin II binds to SHP2 and this interaction is regulated by HSP70 levels. Biochem Biophys Res Commun 356(4): 906-911.
31. Cesarman GM, Guevara CA, Hajjar KA, (1994) An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 269(33): 21198-21203.
32. Kirsch T, Harrison G, Golub EE, Nah HD, (2000) The roles of annexins and types II and X collagen in matrix vesicle-mediated mineralization of growth plate cartilage. J Biol Chem 275(45): 35577-35583.
33. Hayes MJ, Moss SE, (2009) Annexin 2 has a dual role as regulator and effector of v-src in cell transformation. J Biol Chem 284(15): 10202-10210.
34. Grewal T, Enrich C, (2009) Annexins-modulators of EGF receptor signalling and trafficking. Cell Signal 21(6): 847-858.
35. Morel E, Gruenberg J, (2009) Annexin A2 binding to endosomes and functions in endosomal transport are regulated by tyrosine 23 phosphorylation. J Biol Chem 284(3): 1604-1611.
36. Donepudi M, Resh MD, (2008) c-src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling. Cell Signal 20(7): 1359-1367.
37. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, et al. (1999) c-src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274(12): 8335-8343.
38. Das S, Roth CP, Wasson LM, Vishwanatha JK, (2007) Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 67(14): 1550-1564.
39. Vishwanatha JK, Jindal HK, Davis RG, (1992) The role of primer recognition proteins in DNA replication: Association with nuclear matrix in HeLa cells. J Cell Sci 101 (Pt 1)(Pt 1): 25-34.
40. Dasgupta S, Wasson LM, Rauniyar N, Prokai L, Borejdo J, et al. (2009) Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene 28(32): 2860-2872.
41. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, et al. (2005) EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18(8): 1027-1033.
42. Koninki K, Barok M, Tanner M, Staff S, Pitkanen J, et al. (2010) Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 294(2): 211-219.
43. Sharma M, Ownbey RT, Sharma MC, (2010) Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol 88(2): 278-286.
44. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, et al. (2004) Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 113(1): 38-48.
45. Axelrod D, (2001) Total internal reflection fluorescence microscopy in cell biology. Traffic 2(11): 764-774.
46. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, et al. (1993) Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: Prognostic implications. J Natl Cancer Inst 85(7): 570-574.
47. Pinilla SM, Honrado E, Hardisson D, Benitez J, Palacios J, (2006) Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 99(1): 85-90.
48. Kassam G, Le BH, Choi KS, Kang HM, Fitzpatrick SL, et al. (1998) The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry 37(48): 16958-16966.
49. Ribeiro-Silva A, Ribeiro do Vale F, Zucoloto S, (2006) Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am J Clin Pathol 125(4): 512-518.
50. Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C, et al. (2011) Plasminogen activator uPA is a direct transcriptional target of the JAG1-notch receptor signaling pathway in breast cancer. Cancer Res 71(1): 277-286.
51. Takano S, Togawa A, Yoshitomi H, Shida T, Kimura F, et al. (2008) Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol 15(11): 3157-3168.
52. Boyer J, Maxwell PJ, Longley DB, Johnston PG, (2004) 5-fluorouracil: Identification of novel downstream mediators of tumour response. Anticancer Res 24(2A): 417-423.
53. Chuthapisith S, Bean BE, Cowley G, Eremin JM, Samphao S, et al. (2009) Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer 45(7): 1274-1281.
54. Chuthapisith S, Layfield R, Kerr ID, Hughes C, Eremin O, (2007) Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 30(6): 1545-1551.
55. Mohammad HS, Kurokohchi K, Yoneyama H, Tokuda M, Morishita A, et al. (2008) Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol 33(6): 1157-1163.
56. Rescher U, Gerke V, (2004) Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 117(Pt 13): 2631-2639.
57. Rescher U, Ludwig C, Konietzko V, Kharitonenkov A, Gerke V, (2008) Tyrosine phosphorylation of annexin A2 regulates rho-mediated actin rearrangement and cell adhesion. J Cell Sci 121(Pt 13): 2177-2185.
58. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, et al. (2003) Epidermal growth factor receptor: Mechanisms of activation and signaling. Exp Cell Res 284(1): 31-53.